Compare Strategy Inc. (MSTR) vs Novo Nordisk A/S (NVO) Price & Performance

Strategy Inc.Trade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Strategy Inc. vs Novo Nordisk A/S — how do they compare? Strategy Inc. trades at $133.78 (market cap $54.24B), while Novo Nordisk A/S trades at $44.72 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 3.7× Strategy Inc.'s market cap, and Novo Nordisk A/S pays a 3.98% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.

	MSTR	NVO
Market Cap	$54.24B	$200.69B
Sector	Technology	Health
52-Week High	$359.69	$63.98
52-Week Low	$82.31	$35.29
Enterprise Value	$73.00B	$215.49B
Dividend Yield	—	3.98%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Strategy Inc.

MSTR trades at $136.52, down 4.4% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of -$24.45, missing estimates, and has a negative net income margin of -6,102.96%. Recent news highlights a $176.3 million preferred stock buyback instead of Bitcoin purchases, and a partnership with Google Cloud for an AI forum series.

The outlook is mixed: analyst consensus is bullish with a $229.64 price target, but significant risks include persistent earnings misses, high debt, and negative profitability. The stock's performance is heavily tied to Bitcoin market sentiment, posing volatility risks despite institutional interest.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.

NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MSTR

Strategy invests $176.3M in its own preferred stock, halting Bitcoin buys, signaling a shift in capital use.24/7 Wall Street · 14 hours agoBearish Strategy buys 4,603 Bitcoin at $80,300 each, raising total holdings to 845,050 BTC despite recent sales.24/7 Wall Street · 1 day agoNeutral Strategy stock down 56% but one analyst predicts it could triple on Bitcoin rebound.24/7 Wall Street · 2 days agoBullish View details →

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 1 day agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

About Strategy Inc.

MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.